Application of Clinical Judgment and Guidelines to Achieving Glycemic Goals in Type 2 Diabetes: Focus on Pharmacologic Therapy

References

• . Liday C. Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus. Pharmacotherapy. 2011;31( 12 Suppl):37S–43S
   Google Scholar
• . American Diabetes Assocation (ADA). Standards of medical care in diabetes—2014. Diabetes Care. 2014;37( Suppl 1):S14–S80
   Web of Science ®Google Scholar
• . Handelsman Y, Mechanick JI, Blonde L, . American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17( Suppl 2):1–53
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Abrahamson MJ, Barzilay JI, . AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327–336
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Bohannon NJ. Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. Postgrad Med. 2012;124(4):95–108
   PubMed Web of Science ®Google Scholar
• . Raz I, Riddle MC, Rosenstock J, . Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care. 2013;36(6):1779–1788
   PubMed Web of Science ®Google Scholar
• . Steinsbekk A, Rygg LO, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012;12:213
   PubMed Web of Science ®Google Scholar
• . Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch Intern Med. 2008;168(19):2088–2094
   PubMedGoogle Scholar
• . Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev. 2012;64(2):188–237
   PubMed Web of Science ®Google Scholar
• . Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Davidson JA, Blonde L, Jellinger PS, Lebovitz H, Parkin CG. Road map for the prevention and treatment of type 2 diabetes. Endocr Pract. 2006;12( Suppl 1):6–12
   PubMedGoogle Scholar
• . Nathan DM, Buse JB, Davidson MB, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963–1972
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71–72
   PubMed Web of Science ®Google Scholar
• . Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet institute of medicine standards: two more decades of little, if any, progress. Arch Intern Med. 2012;172(21):1628–1633
   PubMedGoogle Scholar
• . Seidu S, Khunti K. Non-adherence to diabetes guidelines in primary care—the enemy of evidence-based practice. Diabetes Res Clin Pract. 2012;95(3):301–302
   PubMed Web of Science ®Google Scholar
• . Vigersky RA. A review and critical analysis of professional societies' guidelines for pharmacologic management of type 2 diabetes mellitus. Curr Diab Rep. 2012;12(3):246–254
   PubMedGoogle Scholar
• . Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3–19
   PubMed Web of Science ®Google Scholar
• . Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–794
   PubMed Web of Science ®Google Scholar
• . Smith RJ, Nathan DM, Arslanian SA, . Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab. 2010;95(4):1566–1574
   PubMed Web of Science ®Google Scholar
• . Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther. 2012;14( Suppl 1):S68–S74
   PubMed Web of Science ®Google Scholar
• . Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia. 2008;51(6):921–925
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Qaseem A, Humphrey LL, Sweet DE, . Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218–231
   PubMed Web of Science ®Google Scholar
• . Monnier L, Colette C. Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. Expert Opin Pharmacother. 2008;9(16):2857–2865
   PubMed Web of Science ®Google Scholar
• . Pozzilli P, Leslie RD, Chan J, . The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev. 2010;26(4):239–244
   PubMedGoogle Scholar
• . Freeman JS, Gross B. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol. 2012;5(1):31–42
   PubMed Web of Science ®Google Scholar
• . Boussageon R, Supper I, Bejan-Angoulvant T, . Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204
   PubMed Web of Science ®Google Scholar
• . Chapell R, Gould AL, Alexander CM. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab. 2009;11(11):1009–1016
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab. 2013;15(9):819–825
   PubMedGoogle Scholar
• . DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309–317
   PubMed Web of Science ®Google Scholar
• . Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508–2514
   PubMed Web of Science ®Google Scholar
• . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885
   PubMed Web of Science ®Google Scholar
• . Hurel SJ, Mohan V. Clinical decision making: managing postprandial hyperglycemia. J Assoc Physicians India. 2006;54:871–876
   PubMedGoogle Scholar
• . Cornell S. Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach. J Clin Pharm Ther. 2012;37(3):254–259
   PubMedGoogle Scholar
• . Schwartz SS. Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes. Drugs in Context. 2013;2013:1–8
   Google Scholar
• . Garber A, Henry RR, Ratner R, . Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348–356
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther. 2012;37(5):510–524
   PubMedGoogle Scholar
• . Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157
   PubMed Web of Science ®Google Scholar
• . Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–613
   PubMed Web of Science ®Google Scholar
• . Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011;34( Suppl 2):S244–S250
   PubMedGoogle Scholar
• . Gaziano JM, Cincotta AH, Vinik A, . Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1(5):e002279
   PubMed Web of Science ®Google Scholar
• . Stenlof K, Cefalu WT, Kim KA, . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382
   PubMed Web of Science ®Google Scholar
• . Florez H, Scranton R, Farwell WR, . Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab. 2011;2(7):1–8
   Google Scholar
• . Zambrowicz B, Ding ZM, Ogbaa I, . Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35(3):273–285, e277
   PubMed Web of Science ®Google Scholar
• . Nadeau DA. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. Postgrad Med. 2013;125(3):112–126
   PubMed Web of Science ®Google Scholar
• . Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014;16(3):193–205
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Rosenstock J, Gerich J; Insulin Glargine Study I. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab. 2008;93(2):372–374
   PubMedGoogle Scholar
• . Rodbard HW, Jellinger PS. A critique of the 2012 ADA/EASD position statement. Diabetologia. 2012;55(10):2850–2852
   PubMed Web of Science ®Google Scholar
• . Matthews DR, Inzucchi SE, for the Position Statement Writing Group. ADA/EASD position statement of the treatment of type 2 diabetes: reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter], and Ceriello A, Gallo M, Gentile S et al [letter]. Diabetologia. 2012;55(10):2856–2857
   PubMedGoogle Scholar
• . Habib ZA, Tzogias L, Havstad SL, . Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):437–447
   PubMedGoogle Scholar
• . Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1969–1970, discussion 1971–1972
   PubMed Web of Science ®Google Scholar
• . Keche Y. Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control. J Pharm Bioallied Sci. 2010;2(2):148–150
   PubMedGoogle Scholar
• . Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31(11):2472–2488
   PubMed Web of Science ®Google Scholar
• . Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf. 2009;32(5):409–418
   PubMedGoogle Scholar